Provided by Tiger Trade Technology Pte. Ltd.

REMEGEN

81.900
+1.1501.42%
Volume:810.77K
Turnover:66.43M
Market Cap:46.16B
PE:-26.48
High:83.700
Open:80.000
Low:80.000
Close:80.750
52wk High:126.600
52wk Low:14.960
Shares:563.61M
HK Float Shares:208.58M
Volume Ratio:0.31
T/O Rate:0.39%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-3.093
ROE:-40.42%
ROA:-9.72%
PB:17.56
PE(LYR):-26.48
PS:18.29

Loading ...

RemeGen (09995.HK / 688331.SH) Announces January 2026 Monthly Securities Movements

Bulletin Express
·
Feb 05

RemeGen to Swing to Profit in 2025

MT Newswires Live
·
Feb 02

Hong Kong Stocks Movement | REMEGEN (09995) Rises Nearly 4% Post Profit Alert; Forecasts 2025 Net Profit Attributable to Owners of Approximately RMB 716 Million, Significantly Improved Profitability Efficiency

Stock News
·
Feb 02

Have Insiders Sold RemeGen Shares Recently?

Simply Wall St.
·
Jan 31

RemeGen (SEHK:9995) Is Down 7.8% After US$650m AbbVie PD-1/VEGF Licensing Deal News - Has The Bull Case Changed?

Simply Wall St.
·
Jan 26

Hong Kong Stock Movement | Rongchang Biotech (09995) Rises Nearly 4% as Institutions See Collaboration with AbbVie Boosting RC148 R&D and Global Commercial Expansion

Stock News
·
Jan 23

RemeGen Completes Share Buyback After First Repurchase

MT Newswires Live
·
Jan 21

RemeGen Lifts Price Cap on Share Repurchase

MT Newswires Live
·
Jan 16

Stock Track | REMEGEN Soars 5.09% Intraday on AbbVie Licensing Deal for RC148

Stock Track
·
Jan 16

HK Market Daily: PBOC Cuts Key Rates by 25bps; State Grid Plans 4 Trillion Yuan "16th Five-Year" Investment

Stock News
·
Jan 16

Assessing RemeGen (SEHK:9995) Valuation After AbbVie RC148 Licensing Agreement

Simply Wall St.
·
Jan 16

Huaxi Securities Maintains "Overweight" Rating on REMEGEN (09995) as RC148 Bispecific Antibody Goes Global in $5.6 Billion Deal

Stock News
·
Jan 15

Zhutong Hong Kong Stock Connect Active Trading | January 13

Stock News
·
Jan 13

RemeGen Sells License to Anti-tumor Medicine RC148; Shares Jump 9%

MT Newswires Live
·
Jan 13

PD-1/VEGF Bispecific Antibody Deal Frenzy Returns? Remegen Inks $5.6 Billion Licensing Agreement

Deep News
·
Jan 13

Stock Track | REMEGEN Soars 8.84% in Pre-Market on Exclusive Licensing Deal with AbbVie

Stock Track
·
Jan 13

Zhitoing HK Stock Morning Briefing | Four Ministries Issue Trial Work Measures on Government Investment Fund Layout and Guidance; Overnight China Concept Stock Index Rises 4.26%

Stock News
·
Jan 13

REMEGEN (09995) Signs Exclusive Licensing Agreement with AbbVie for RC148

Stock News
·
Jan 12

Hong Kong Stock Movement | REMEGEN (09995) Surges Over 11%, Institutions Indicate It's on Accelerated Commercialization Track

Stock News
·
Jan 07

REMEGEN (09995) Had Not Commenced Share Repurchase as of December 31

Stock News
·
Jan 05